Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients

Hull, Mark; Montaner, Julio S. G.

doi:10.1517/14656561003724754

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ETV combined with DRV boosted with ritonavir is used in the treatment of experienced patients that have drug-resistant HIV infections [19], and several clinical trials preceded this approach.…”

Section: Combination Of Etv and Drvmentioning

confidence: 99%

A Review Concerning the Use of Etravirine and Darunavir in Translational Medicine

Pereira,

Vale

2023

IJTM

View full text Add to dashboard Cite

This comprehensive review explores two antiretroviral drugs, Etravirine (ETV) and Darunavir (DRV), a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor, that are commonly used in human immunodeficiency virus (HIV) infection treatment, often in combination with each other. The pharmacokinetic properties of these drugs are covered as well as the clinical trials of these two drugs combined. This paper also delves into the possible repurposing of these two drugs for other diseases, with drug repurposing being a significant factor in addressing global health challenges. DRV was extensively studied for treating COVID-19, as well as other infections, such as candidiasis and cryptococcosis, while ETV proved to be efficient in hampering Zika virus brain infection. The focus on cancer repurposing is also explored, with the results revealing that ETV has a particular inhibitory effect on ovarian cancer in vitro and on cancer molecules, such as anterior gradient protein 2 homolog (AGR2) and casein kinase 1 (CK1ε), and that DRV has an in silico inhibitory effect on human lactate dehydrogenase A (LDHA) and induces the in vitro and in vivo inhibition of pepsin, consequent laryngopharyngeal reflux, and possible laryngeal and hypopharyngeal carcinomas. The significance of fresh methods of drug development is emphasized in this work, as is the enormous potential for new therapeutic uses of the antiretroviral drugs ETV and DRV in viral and non-viral disorders.

show abstract

Section: Combination Of Etv and Drvmentioning

confidence: 99%

A Review Concerning the Use of Etravirine and Darunavir in Translational Medicine

Pereira,

Vale

2023

IJTM

View full text Add to dashboard Cite

show abstract

A benchmark for management of drug resistant HIV

Pozniak¹,

Arribas²

2013

The Lancet Infectious Diseases

View full text Add to dashboard Cite

Nephrotoxicity of HAART

Kalyesubula

Perazella

2011

AIDS Research and Treatment

View full text Add to dashboard Cite

Highly active antiretroviral therapy (HAART) and other medical therapies for HIV-related infections have been associated with toxicities. Antiretroviral therapy can contribute to renal dysfunction directly by inducing acute tubular necrosis, acute interstitial nephritis, crystal nephropathy, and renal tubular disorders or indirectly via drug interactions. With the increase in HAART use, clinicians must screen patients for the development of kidney disease especially if the regimen employed increases risk of kidney injury. It is also important that patients with chronic kidney disease (CKD) are not denied the best combinations, especially since most drugs can be adjusted based on the estimated GFR. Early detection of risk factors, systematic screening for chronic causes of CKD, and appropriate referrals for kidney disease management should be advocated for improved patient care. The interaction between immunosuppressive therapy and HAART in patients with kidney transplants and the recent endorsement of tenofovir/emtricitabine by the Centers for Disease Control (CDC) for preexposure prophylaxis bring a new dimension for nephrotoxicity vigilance. This paper summarizes the common antiretroviral drugs associated with nephrotoxicity with particular emphasis on tenofovir and protease inhibitors, their risk factors, and management as well as prevention strategies.

show abstract

Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients

Cited by 3 publications

References 17 publications

A Review Concerning the Use of Etravirine and Darunavir in Translational Medicine

A Review Concerning the Use of Etravirine and Darunavir in Translational Medicine

A benchmark for management of drug resistant HIV

Nephrotoxicity of HAART

Contact Info

Product

Resources

About